Broker tips Fisher & Paykel Healthcare (ASX:FPH) share price to go even higher

The Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) share price is up 50% in 2020. Can it go even higher?
The post Broker tips Fisher & Paykel Healthcare (ASX:FPH) share price to go even higher appeared first on Motley Fool Australia. –

is it a buy

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price has been a very strong performer in 2020.

Since the start of the year, the medical device company’s shares have risen a remarkable 50%.

Why is the Fisher & Paykel Healthcare share price up 50% this year?

Investors have been scrambling to buy Fisher & Paykel Healthcare’s shares this year after the COVID-19 pandemic led to a surge in its sales and profits.

Yesterday, the company released its half year results and revealed a 59% increase in operating revenue to NZ$910.2 million and an 86% jump in net profit after tax to NZ$225.5 million.

This was driven by strong demand for its hospital hardware, particularly its Optiflow and Airvo systems. Traditionally, this nasal high flow therapy is used in clinical practices but has shifted as a front-line treatment for COVID-19 patients in hospitals.

Management appears optimistic that the second half will be strong and has lifted its expectations for FY 2021.

Based on current assumptions, it estimates that full year revenue could come in at NZ$1.72 billion and net profit after tax would be between NZ$400 million to NZ$415 million. The latter is up from its previous expectation for profit after tax of NZ$365 million to NZ$385 million. 

Is it too late to buy Fisher & Paykel Healthcare shares?

According to one leading broker, it’s not too late to make an investment in Fisher & Paykel Healthcare’s shares.

This morning analysts at Goldman Sachs retained their buy rating and bumped their price target higher to $37.60.

The broker notes that high-flow therapy continues to build momentum and it sees an attractive penetration runway ahead.

Goldman commented: “High-flow penetration of conventional oxygen therapy probably sits between 10-20%, and we see limited reasons why 50%+ is not possible over the mid/long-term. Clinical and regulatory feedback have been increasingly supportive, and we expect the forward penetration trajectory to have steepened through recent periods.”

“FPH reiterated today that Optiflow and Airvo are ‘nowhere near’ market saturation. FPH upgraded FY21 guidance for the second time today (after four upgrades in FY20). With near-term momentum accelerating rather than slowing, we expect at least one further upgrade in the remainder of the year and upgrade our FY21 earnings estimate by 11% to $426m (+5% above mid-point of range),” it added.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Broker tips Fisher & Paykel Healthcare (ASX:FPH) share price to go even higher appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!